NEW YORK (GenomeWeb News) - Sloning Biotechnology said today it has raised €4.7 million ($6.8 million) in Series E venture financing from one new and several previous investors.
Sloning, based in Puchheim, Germany, plans to use the cash to commercialize its Slonomics gene synthesis business internationally and to expand its Slonomax gene mutant library product line.
The round of funding included new investor LBBW Venture Capital and existing investors HBM BioVentures, KfW Bankengruppe, and Deutsche Effecten- und Wechsel-Beteiligungsgesellschaft.
With the investment, LBBW’s Harold Poth will become a non-executive director at Sloning.
BioConnect of Frankfurt am Main, Germany, served as financial advisor to the company in the funding round.